HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $40 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 85.8%

Neg 0% Neu 85.8% Pos 0%

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $40 price target.